Brain atrophy as an outcome measure for multiple sclerosis clinical trials: A "no-brainer"?

Neurology

Volumn 72, Issue 7, 2009, Pages 586-587

  Rudick, Richard A ^a   Fisher, Elizabeth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERFERON BETA SERINE; NEUROPROTECTIVE AGENT;

BRAIN ATROPHY; BRAIN EDEMA; BRAIN SIZE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; ENCEPHALITIS; GRAY MATTER; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; ATROPHY; BRAIN; METHODOLOGY; NOTE; PATHOLOGY;

ATROPHY; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 61849106994     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000342478.46908.79     Document Type: Editorial

References (9)

1. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893-901.
2. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
3. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255-265.
4. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158-170.
5. Altmann DR, Jasperse B, Barkhof F, et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009:72:595-601.
6. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis: European Study Group on Interferon beta-1b in secondarypro-gressive multiple sclerosis. Brain 2000;123:2256-2263.
7. Smith SM, De SN, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001:25:466-475.
8. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS: Multiple Sclerosis Collaborative Research Group. Neurology 1999:53:1698-1704.
9. Hardmeier M, Wagenpfeil S, Freitag P, et al. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. Arch Neurol 2003:60:1736-1739.